Diagnostic imaging isn’t a tidy industry category — it’s scattered across health services and a few industrial classifications, so there’s no clean list to pull. We built one by name and activity (radiology, imaging, MRI, X-ray, ultrasound, PET-CT, teleradiology), then stripped out the false positives — in-vitro diagnostics and reagent businesses (Roche, Siemens Healthineers), equipment makers, and pure name collisions (MRI Software is property management). What remains is the set of UK companies whose primary activity is providing imaging services, plus adjacent teleradiology, radiopharmacy and private radiotherapy. Nineteen publish a full profit-and-loss; together they book ~£867M of turnover and employ ~5,600 staff.
Three caveats shape everything below, and they matter more here than in most sectors:
- What you can see is a fraction of the activity. The bulk of UK imaging happens inside hospital groups (HCA, Spire, Bupa, Nuffield, Ramsay, every NHS trust) where scan revenue is consolidated into hospital turnover. The £867M visible here is the standalone-imaging-services market, not the UK imaging market — which runs into the multi-billions.
- The UK’s largest teleradiology business is invisible. Medica Reporting doesn’t publish a full profit-and-loss of its own, so it can’t be ranked here. Treat it as absent but likely top-three.
- Figures are approximate — verify any single number against a company’s own accounts. This is analysis, not financial advice.
The headline: a bimodal market with no healthy middle
The single clearest finding is that UK diagnostic imaging is bimodal. Two business models share the label and have opposite financial physics:
- The NHS-contracted scale networks (Alliance Medical £212M, InHealth £185M) run thousands of scans a week at framework prices — and are loss-making or barely profitable in their UK entities. Alliance Medical posted a −£52M year.
- The private single-site centres (Devonshire, Welbeck Street, Wellington, London Radiotherapy) bill at private/self-pay rates and run at 35–45% margins, growing fast on self-pay demand.
Never blend the two. The chart below is the whole thesis in one frame: median profit margin by segment, from NHS-contracted scale on the left to private-pay single-site on the right.
The giants — and their losses
There are only two genuine giants in the visible market, and both are struggling.
| Company | Turnover | PBT | Turnover YoY | Owner |
|---|---|---|---|---|
| Alliance Medical | £211.9M | −£52.1M | +5.4% | iCON Infrastructure (acquired Jan 2024, £910M enterprise value) |
| InHealth | £185.0M | £3.3M | +8.9% | The Damask Trust (founder trust) |
Alliance Medical’s swing — from a +£163M prior year to −£52M — is the biggest single red flag in the data, and it has a clean explanation: the prior year almost certainly bundled a one-off gain tied to the £910M sale to iCON, and the current year is the first full year under the new infrastructure-PE owner (which also extracted a £30M dividend). Read it as first-year-under-new-owner, not ongoing performance. InHealth is the cleaner story: revenue growing healthily, but PBT collapsed 75% as staff costs rose faster than NHS framework prices. Notably, InHealth is the largest UK imaging asset still unconsolidated by a financial sponsor — held in a founder/family trust while Medica (→ IK Partners), 4 Ways (→ Evidia/EQT) and Alliance (→ iCON) have all been bought.
Where the money actually is: the private-pay tier
Filtered to genuine operators that are profitable, growing and high-margin, the picture inverts the usual “bigger is better”: the most attractive unit economics in the entire visible set are the small, central-London private-pay centres.
| Company | Sub-type | Turnover | PBT | Margin | Turnover YoY |
|---|---|---|---|---|---|
| Devonshire Diagnostic Centre | private single-site | £51.4M | £20.4M | 39.8% | +47.5% |
| London Radiotherapy Centre | private radiotherapy | £18.3M | £8.3M | 45.4% | +28.2% |
| Everlight Radiology | teleradiology | £67.0M | £11.3M | 16.8% | +15.8% |
| 4 Ways Healthcare | teleradiology | £47.0M | £9.7M | 20.6% | stable |
| Medical Imaging Systems | equipment-financed | £46.5M | £8.7M | 18.8% | +30.1% |
| Alliance Medical Radiopharmacy | PET tracers | £46.0M | £8.1M | 17.6% | +19.0% |
| Welbeck Street Diagnostic Centre | private single-site | £6.9M | £3.0M | 43.6% | +16.0% |
| Wellington Diagnostic Services | private single-site | £4.2M | £1.5M | 35.4% | +11.0% |
The standouts: Devonshire — an HCA Healthcare UK facility — does £51M at a 40% margin and grew turnover +47% while more than doubling headcount, a single central-London address scaling into private-self-pay demand. London Radiotherapy runs the highest margin in the set at 45%. The plotting below puts every named operator on growth-versus-margin: the private-pay tier sits top-right (growing and highly profitable), Alliance Medical sits alone in the loss quadrant, and the teleradiology/radiopharmacy cluster sits comfortably profitable in the middle.
Two cautions on this tier. First, all the high-margin private-pay specialists are in central London — this is the London private-medicine economy, not a national pattern; replicating it outside zones 1–2 is materially harder. Second, 4 Ways paid a £27M dividend against £10M of profit — roughly three years’ earnings — consistent with a PE owner recycling cash (Evidia/EQT acquired it in 2023).
Six business models behind one label
Beneath the single label sit at least six distinct models, each responding to a different demand driver. The taxonomy is what explains the bimodal margin chart — Alliance Medical’s negative margin isn’t “imaging is broken”, it’s the NHS-framework model under price pressure; Devonshire’s 40% isn’t “London is special”, it’s the private-pay single-site model working normally.
The cleanest single signal separating these models is cost per head — staff cost divided by employees. It exposes the teleradiology business model instantly:
The deeper structural point: the buyer determines the margin. Splitting the 19 firms by who pays them, NHS-dominant firms are stressed regardless of operational quality (combined median margin ~−2%); private-pay-dominant firms are healthy regardless of scale (~40%); mixed and B2B firms split the difference. Anyone entering this market has to choose their buyer first.
Ownership: a PE-consolidated market, with one big exception
Imaging is overwhelmingly an institutional / PE-owned market, not a founder market — and financial-sponsor consolidation has hit three of the four largest standalone assets in the last 24 months: Medica → IK Partners (2023 take-private), 4 Ways → Evidia / EQT Infrastructure (2023), Alliance Medical → iCON Infrastructure (Jan 2024). The notable exception is InHealth, still in a founder trust. The central-London private-pay single-site tier is thinner than it first looks, though: the standout Devonshire is not an independent at all — it sits inside HCA Healthcare UK (via The Physicians Clinic), the US hospital group whose wider imaging volumes are invisible inside its hospitals. That leaves the Welbeck Street and Wellington LLPs as the remaining partner-owned single-site operators — LLP structures suit high-distribution clinical partnerships, and single-clinic deals at their size are too small for the funds active here. On this data those two are the most attractive un-rolled-up assets in the visible market, though at £4–7M of turnover they are an order of magnitude smaller than Devonshire.
What the map shows
- The visible market (~£867M) is small because most imaging is inside hospital groups. Any sector-wide claim has to start there.
- Two business models, opposite margins. NHS-contracted scale operates near or below zero; private-pay single-site operates at 35–45%. Don’t blend them.
- Teleradiology is the structural winner of the last five years — asset-light, subcontractor-radiologist economics, 16–21% margins, already being consolidated by PE.
- Central-London private-pay is its own market — the best unit economics in UK health-services visible here, and not generalisable to the regions.
- NHS-framework scale is in distress — Alliance’s £52M loss and InHealth’s 75% PBT collapse reflect framework price compression colliding with payroll inflation.
- The mid-tier independent mobile/community operator is the kill zone — too small to win frameworks, too distributed to capture single-site economics.
Methodology and caveats
This set was built by name and activity (no tidy imaging category exists) and de-duplicated against in-vitro diagnostics, equipment makers and name collisions; most imaging-related companies are too small to report figures (consultant-radiologist personal companies, single-scanner partnerships), and Medica Reporting — likely the largest pure teleradiology business in the UK — doesn’t publish a full profit-and-loss of its own and is invisible here. Segment and sub-type labels combine name, activity, cost-per-head signature and known industry positioning — directional, not definitive. Figures are approximate; ownership notes are from public sources as of the report date. No company named here is known to be for sale, distressed beyond what its accounts state, or seeking investment.